Journal
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
Volume 10, Issue 12, Pages 1315-+Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cgh.2012.07.006
Keywords
Ulcerative Colitis; Colectomy; Inflammatory Bowel Disease; Inpatient Management
Categories
Funding
- Abbott
- ActoGenIX NV
- AGI Therapeutics, Inc
- Alba Therapeutics Corp
- Albireo
- Alfa Wasserman
- Amgen
- AM-Pharma BV
- Anaphore
- Astellas
- Athersys, Inc
- Atlantic Healthcare, Ltd
- Aptalis
- BioBalance Corp
- Boehringer-Ingelheim
- Bristol-Myers Squibb
- Celgene
- Celek Pharmaceuticals
- Cellerix SL
- Cerimon Pharmaceuticals
- ChemoCentryx
- CoMentis
- Cosmo Technologies
- Coronado Biosciences
- Cytokine Pharmasciences
- Eagle Pharmaceuticals
- EnGene, Inc
- Eli Lilly
- Enteromedics
- Exagen Diagnostics, Inc
- Ferring Pharmaceuticals
- Flexio Therapeutics, Inc
- Funxional Therapeutics, Ltd
- Genzyme, Corp
- Gilead Sciences
- Given Imaging
- GSK
- Human Genome Sciences
- Ironwood Pharmaceuticals
- KaloBios Pharmaceuticals
- Lexicon Pharmaceuticals
- Lycera Corp
- Meda Pharmaceuticals
- Merck Research Laboratories
- Merck Serono
- Millennium Pharmaceuticals
- Nisshin Kyorin Pharmaceuticals
- Novo Nordisk
- NPS Pharmaceuticals
- Optimer Pharmaceuticals
- Orexigen Therapeutics, Inc
- PDL Biopharma
- Pfizer
- Procter and Gamble
- Prometheus Laboratories
- ProtAb, Ltd
- Purgenesis Technologies, Inc
- Relypsa, Inc
- Roche
- Salient Pharmaceuticals
- Salix Pharmaceuticals
- Santarus
- Schering Plough
- Shire Pharmaceuticals
- Sigmoid Pharma, Ltd
- Sirtris Pharmaceuticals
- SLA Pharma UK, Ltd
- Targacept
- Teva Pharmaceuticals
- Therakos
- Tilliotts Pharma AG
- TxCell SA
- UCB Pharma
- Viamet Pharmaceuticals
- Vascular Biogenics, Ltd
- Warner Chilcott UK, Ltd
- Wyeth
- Genentech
- Janssen
- Novartis
Ask authors/readers for more resources
Ulcerative colitis is a chronic inflammatory disease of the colon; as many as 25% of patients with this disease require hospitalization. The goals of hospitalization are to assess disease severity, exclude infection, administer rapidly acting and highly effective medication regimens, and determine response. During hospitalization, patients should be given venous thromboembolism prophylaxis and monitored for the development of toxic megacolon. Patients who do not respond to intravenous corticosteroids should be considered for rescue therapy with infliximab or cyclosporine. Patients who are refractory to medical therapies or who develop toxic megacolon should be evaluated promptly for colectomy. Patients who do respond to medical therapies should be discharged on an appropriate maintenance regimen when they meet discharge criteria. We review practical evidence-based management principles and propose a day-by-day algorithm for managing patients hospitalized for ulcerative colitis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available